Bayvrio offers unbranded biosimilar to expand payer choice, access, and affordability
Clinically interchangeable drug will be available to any licensed specialty pharmacy in the U.S. through Bayvrio Marketplace supplier, Birdi, Inc.
Bayvrio today announced that an unbranded biosimilar ustekinumab-aekn, an FDA-designated interchangeable to Stelara® (ustekinumab), is now available through the Bayvrio Marketplace. This addition marks another milestone in Bayvrio’s mission to give healthcare payers, PBMs, and health systems the flexibility to design and manage pharmacy benefit programs that advance their unique strategies and goals.
The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available from Birdi, Inc., a Bayvrio Marketplace wholesale supplier, by any licensed specialty pharmacy in the United States.
“Specialty drugs remain one of the greatest cost drivers for payers, yet access and affordability are still constrained by legacy supply models,” said Mike Napolitano, President of Bayvrio. “By adding biosimilar options to our marketplace, Bayvrio is expanding payer choice and ensuring that value and flexibility go hand in hand.”
Transparency and direct access
The unbranded ustekinumab-aekn bypasses traditional layers of markup in the specialty drug supply chain – allowing payers, pharmacies, and patients to benefit directly from lower acquisition costs. This approach enhances price transparency, affordability, and alignment across all stakeholders while maintaining the same clinical efficacy and safety as the reference drug.
The biosimilar is expected to be available for purchase beginning January 1, 2026.
Flexibility through modularity
The Bayvrio Marketplace enables organizations to implement a full suite of proven pharmacy benefit solutions or integrate individual modules, such as integrated cash, international sourcing, rebate management, price transparency, and specialty programs, into their own benefit design. This modular structure allows payers to create the right configuration for their populations while maintaining full control, interoperability, and visibility.
“Every payer’s strategy is different,” said Napolitano. “Our marketplace gives them the tools and transparency to choose the partners and products that work best for them – including high-value options like this new unbranded biosimilar.”
###
About Bayvrio
Bayvrio brings a bold and innovative approach to pharmacy benefits – one grounded in decades of healthcare experience and a relentless focus on driving value. Its modular, tech-driven approach enables innovation and unprecedented flexibility, giving healthcare payers the freedom to build their own pharmacy benefit strategy. With its transformative technology and curated, best-in-class solutions, Bayvrio empowers clients to take control of their pharmacy benefits, optimize costs and revenue, drive better outcomes, and simplify experiences. To learn more, visit Bayvrio online, follow Bayvrio on LinkedIn, or contact Bayvrio at updates@bayvrio.com.